Valganciclovir as add-on to standard therapy in glioblastoma patients
G Stragliotto, MR Pantalone, A Rahbar, J Bartek… - Clinical Cancer …, 2020 - AACR
Clinical Cancer Research, 2020•AACR
Purpose: Several groups have reported a prevalence of human cytomegalovirus (CMV) in
glioblastoma close to 100%. Previously, we reported that treatment with the antiviral drug
valganciclovir as an add-on to standard therapy significantly prolonged survival in 50
patients with glioblastoma. Here, we present an updated retrospective analysis that includes
an additional 52 patients. Experimental Design: From December 2006 to November 2019,
102 patients with newly diagnosed glioblastoma received valganciclovir as an add-on to …
glioblastoma close to 100%. Previously, we reported that treatment with the antiviral drug
valganciclovir as an add-on to standard therapy significantly prolonged survival in 50
patients with glioblastoma. Here, we present an updated retrospective analysis that includes
an additional 52 patients. Experimental Design: From December 2006 to November 2019,
102 patients with newly diagnosed glioblastoma received valganciclovir as an add-on to …
Purpose
Several groups have reported a prevalence of human cytomegalovirus (CMV) in glioblastoma close to 100%. Previously, we reported that treatment with the antiviral drug valganciclovir as an add-on to standard therapy significantly prolonged survival in 50 patients with glioblastoma. Here, we present an updated retrospective analysis that includes an additional 52 patients.
Experimental Design
From December 2006 to November 2019, 102 patients with newly diagnosed glioblastoma received valganciclovir as an add-on to standard therapy. No additional toxicity was observed. Contemporary controls were 231 patients with glioblastoma who received similar baseline therapy.
Results
Patients with newly diagnosed glioblastoma receiving valganciclovir had longer median overall survival (OS 24.1 vs. 13.3 months, P < 0.0001) and a 2-year survival rate (49.8% vs. 17.3%) than controls. Median time-to-tumor progression was also longer than in controls; 9.9 (0.7–67.5 months) versus 7.3 (1.2–49 months), P = 0.0003. Valganciclovir improved survival in patients with radical or partial resection and an unmethylated or methylated MGMT promoter gene.
Conclusions
Valganciclovir prolonged median OS of patients with newly diagnosed glioblastoma (with methylated or unmethylated MGMT promoter gene) and was safe to use.
AACR
以上显示的是最相近的搜索结果。 查看全部搜索结果